Singapore, April 11 -- Belief BioMed (BBM) and Takeda Chinahave jointly announced that BBM-H901(generic name:Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency).

As the first approved hemophilia B gene therapy in China, BBM-H901 is developed and manufactured by BBM, and Takeda China is responsible for its commercialisation in mainland China, Hong Kong and Macau.

The two parties will integrate their respective resource advantages to accelerate the provision of this breakthrough gene therapy to patients and jointly open up a new landscape in the field of ...